Deciphera Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Deciphera Pharmaceuticals, Inc.
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Deciphera Pharmaceuticals, LLC